Sign Up Today and Learn More About Neurogene Stock
Invest in or calculate the value of your shares in Neurogene or other pre-IPO companies through EquityZen's platform.
Neurogene Stock (NEUO)
Neurogene is a developer of genetic medicines intended to improve patient outcomes for neurological disorders.
About Neurogene Stock
Founded
2018
Headquarters
New York, NY, US
Industries
Software, Artificial Intelligence, Data and Analytics
Neurogene Press Mentions
Stay in the know about the latest news on Neurogene
Neurogene Reports Positive Interim Efficacy Data from First Four Low-Dose Pediatric Participants in NGN-401 Gene Therapy Clinical Trial for Rett Syndrome
businesswire • Nov 12, 2024
Neurogene announces RMAT designation for NGN-401
thefly • Aug 09, 2024
Neurogene Announces First Patient Dosed in High-Dose Cohort of NGN-401 Gene Therapy Clinical Trial for Rett Syndrome
finance • Aug 04, 2024
Neurogene shares get Outperform rating with $65 target
investing • Aug 04, 2024
Neurogene Presents Favorable Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome during ASGCT Annual Meeting
finance • Aug 04, 2024
Neurogene Management
Leadership team at Neurogene
Founder, President, & CEO
Rachel McMinn
Member Board Of Directors
Srdjan Stankovic
Join now and verify your accreditation status to gain access to:
- Neurogene current valuation
- Neurogene stock price
- Available deals in Neurogene and all other companies
- Deal offering documents
- EquityZen's proprietary data and insights, including
- Cap tables, which include funding history by Share Class and Liquidity Preferences
- Company Highlights
- Business Model
- Risk Factors
Trading Neurogene Stock
How to invest in Neurogene stock?
Accredited investors can buy pre-IPO stock in companies like Neurogene through EquityZen funds. These investments are made available by existing Neurogene shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell Neurogene stock?
Shareholders can sell their Neurogene stock through EquityZen's private company marketplace. EquityZen's network includes over 340K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 44K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
